Orna Therapeutics
Address: 500 Forge Road,, Watertown, MA 02472About Us
Orna Therapeutics is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease.
Sectors
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Licensing
- Collaborations & Partnerships-Manufacture
- Proprietary Research & Manufacture
- Contract Research & Development
- Gene/RNA Delivery Technology
Categories
- Biologics
- Messenger RNA
- RNA based Products
- RNA-Circular
- Clinical Development-Pipeline
- Bioinformatics
- Lipids
- Lipid Nanoparticles (LNPs)
- Gene Delivery Technology
- Platform Technology-Drug Development
- Platform Technology-Drug Discovery
- Cell Therapy
- Cell Therapy Products
- Immunotherapy
News
Lilly to acquire Orna Therapeutics to advance cell therapies
INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.
Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can treat underlying disease. Orna’s lead program is ORN-252, a clinical trial-ready, CD19 targeting in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to treat B cell-driven autoimmune diseases. Experiments to date suggest that Orna’s circular RNA platform may deliver more durable expression of therapeutic proteins and therefore unlock treatments that are not feasible with current RNA or cell therapy platforms.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com